ClinicalTrials.gg
CompletedNCT02547701Updated Mar 8, 2018

Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population

A Phase 3 interventional study of P-3058 in Onychomycosis, sponsored by Polichem S.A.. Completed at 5 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2014, registered Sep 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Study summary

Pediatric patients affected by mild-to-moderate distal subungual onychomycosis (DSO) or affected by white superficial onychomycosis (WSO), due to dermatophytes, will be treated topically with P-3058 nail solution according to the appropriate treatment schedule.

02

Conditions studied

  • Onychomycosis

Browse trials for

03

In context

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 143 interventional studies indexed under Onychomycosis.

Browse Onychomycosis studies →

Lead sponsor

Polichem S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before Polichem S.A. became part of Almirall, S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 2 to 17 years
  • Males and females
  • Clinical diagnosis of mild-to-moderate distal sub-ungual onychomycosis without spikes/dermatophytoma and without lunula involvement or white superficial onychomycosis.
  • Positive mycroscopy examination from the target nail at screening.
  • Positive culture for dermatophyte from the target nail at screening.

Exclusion criteria

Exclusion Criteria:

  • Patients with onychomycosis caused by yeasts or non-dermatophytes mould.
  • Patients with nail psoriasis.
  • Patients with nail changes due to eczema, lichen planus or alopecia areata.
  • Patients with one-hand two-foot syndrome.
  • Patients with immunodeficiency disorder or use of immune suppressive therapy 3 months prior to screening visit or need for it.
  • Use of systemic antifungal drugs in the 6 months prior to screening visit.
  • Use of topical nail antifungal drugs in the four weeks prior to screening visit.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    P-3058

    Drug: P-3058

Interventions

  • DrugP-3058
06

What researchers measure

Primary outcomes

  1. Local tolerability

    Local tolerability at all treated nails by means of the Severity Score for Skin Irritation

    Time frame: from week 4 up to maximum week 48 of treatment

07

Study locations

5 sites
  • Polichem Investigative site
    One Investigational Site, Belgium
  • Polichem Investigative Site
    One Investigational Site, Germany
  • Polichem Investigative site
    One Investigational Site, Italy
  • Polichem Investigative Site
    One Investigational Site, Latvia
  • Polichem Investigative Site
    One Investigational Site, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Sep 2017, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2015
First posted
Sep 11, 2015
StartActual
Aug 2014
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Last update
Mar 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02547701
Lead sponsor
Polichem S.A.
Responsible party
Sponsor
First posted
Sep 11, 2015
Start date
Aug 2014
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Mar 8, 2018

Study contacts

Maurizio Caserini, MD
study director · Polichem SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion